Pancreatic Neuroendocrine Tumors

Oncology
1
Pipeline Programs
2
Companies
50
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Verona Pharma
Verona PharmaUK - London
1 program
1
NIRPhase 11 trial
Active Trials
NCT02685553Completed10Est. Oct 2016
Pfizer
PfizerNEW YORK, NY
1 program
sunitinibN/ASmall Molecule5 trials
Active Trials
NCT05745142Completed376Est. Feb 2023
NCT04669366Completed1,205Est. Mar 2022
NCT03916458Completed62Est. Nov 2020
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Pfizersunitinib
Pfizersunitinib
Pfizersunitinib
Pfizersunitinib
Pfizersunitinib
Pfizersunitinib
Pfizersunitinib
Pfizersunitinib
Pfizersunitinib
Pfizersunitinib
Pfizersunitinib
Pfizersunitinib
Pfizersunitinib
Pfizersunitinib
Pfizersunitinib

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 6,866 patients across 50 trials

NCT00793871Pfizersunitinib

Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor

Start: Nov 2008Est. completion: Oct 201460 patients
Phase 4Completed
NCT00706706Pfizersunitinib

Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma

Start: Jul 2008Est. completion: Aug 2011105 patients
Phase 4Completed
NCT03013946Pfizersunitinib

Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Start: Jan 2017Est. completion: Jan 2024121 patients
Phase 3Terminated
NCT00930033Pfizersunitinib

Clinical Trial to Assess the Importance of Nephrectomy

Start: Sep 2009Est. completion: Oct 2018452 patients
Phase 3Completed
NCT00699374Pfizersunitinib

Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

Start: Jul 2008Est. completion: Dec 20111,075 patients
Phase 3Terminated
NCT00474786Pfizersunitinib

Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib

Start: Sep 2007Est. completion: Jan 2013512 patients
Phase 3Completed
NCT00393939Pfizersunitinib

Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer

Start: Feb 2007Est. completion: Jul 2011594 patients
Phase 3Completed
NCT00435409Pfizersunitinib

A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer

Start: Feb 2007Est. completion: Jun 2011442 patients
Phase 3Completed
NCT00373113Pfizersunitinib

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

Start: Nov 2006Est. completion: Jun 2011482 patients
Phase 3Terminated
NCT00373256Pfizersunitinib

A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

Start: Nov 2006Est. completion: Aug 2011488 patients
Phase 3Completed
NCT03297606Pfizersunitinib

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Start: Mar 2018Est. completion: Jan 2027720 patients
Phase 2Recruiting
NCT03592199Pfizersunitinib

Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib

Start: Dec 2017Est. completion: Dec 20227 patients
Phase 2Unknown
NCT03035630Pfizersunitinib

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Start: May 2017Est. completion: Dec 20200
Phase 2Withdrawn
NCT02713763Pfizersunitinib

Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib

Start: Feb 2017Est. completion: Oct 201911 patients
Phase 2Completed
NCT02689167Pfizersunitinib

Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma

Start: Feb 2016Est. completion: Feb 2024226 patients
Phase 2Unknown
NCT02402062Pfizersunitinib

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Start: May 2015Est. completion: Jan 202017 patients
Phase 2Completed
NCT02068586Pfizersunitinib

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Start: Nov 2014Est. completion: Dec 2025210 patients
Phase 2Active Not Recruiting
NCT02400385Pfizersunitinib

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

Start: Oct 2014Est. completion: Dec 20150
Phase 2Withdrawn
NCT02060370Pfizersunitinib

Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)

Start: Aug 2014Est. completion: Jan 201960 patients
Phase 2Completed
NCT02019576Pfizersunitinib

Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib

Start: May 2014Est. completion: Mar 202138 patients
Phase 2Completed
NCT02928575Pfizersunitinib

Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma

Start: Aug 2012Est. completion: Jun 201745 patients
Phase 2Unknown
NCT01396148Pfizersunitinib

A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor

Start: Jun 2012Est. completion: Aug 20176 patients
Phase 2Completed
NCT01499121Pfizersunitinib

Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule

Start: May 2012Est. completion: Sep 2017117 patients
Phase 2Completed
NCT01402817Pfizersunitinib

Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas

Start: Mar 2012Est. completion: Feb 201819 patients
Phase 2Terminated
NCT01070186Pfizersunitinib

Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma

Start: Oct 20100
Phase 2Withdrawn
NCT01108445Pfizersunitinib

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

Start: Sep 2010Est. completion: Apr 2015131 patients
Phase 2Completed
NCT01121562Pfizersunitinib

Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Start: Jul 2010Est. completion: Nov 201312 patients
Phase 2Completed
NCT01042795Pfizersunitinib

Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

Start: Sep 2009Est. completion: Jan 20137 patients
Phase 2Terminated
NCT00556205Pfizersunitinib

Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma

Start: Sep 2009Est. completion: Sep 20090
Phase 2Withdrawn
NCT00982657Pfizersunitinib

A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma

Start: Sep 2009Est. completion: Mar 201434 patients
Phase 2Terminated
NCT00961571Pfizersunitinib

Sunitinib and Capecitabine for First Line Colon Cancer

Start: Aug 2009Est. completion: Mar 201150 patients
Phase 2Terminated
NCT00912912Pfizersunitinib

Sunitinib Malate in Refractory Germ Cell Tumors

Start: May 2009Est. completion: Dec 20145 patients
Phase 2Terminated
NCT00859339Pfizersunitinib

Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

Start: Mar 2009Est. completion: Apr 20119 patients
Phase 2Terminated
NCT00864721Pfizersunitinib

Sunitinib Non Small Cell Lung Cancer Patients Over 70

Start: Feb 2009Est. completion: Jul 201263 patients
Phase 2Completed
NCT00843037Pfizersunitinib

Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma

Start: Feb 2009Est. completion: Mar 202225 patients
Phase 2Completed
NCT01019798Pfizersunitinib

Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer

Start: Jan 2009Est. completion: Dec 201116 patients
Phase 2Unknown
NCT00734851Pfizersunitinib

Multimodality Phase II Study in Prostate Cancer

Start: Dec 2008Est. completion: Nov 201436 patients
Phase 2Terminated
NCT01118351Pfizersunitinib

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Start: Oct 2008Est. completion: Sep 201519 patients
Phase 2Terminated
NCT00730353Pfizersunitinib

Sutent + Taxol for Advanced Esophageal Cancer

Start: Aug 2008Est. completion: Mar 201028 patients
Phase 2Completed
NCT00702884Pfizersunitinib

Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer

Start: Jun 2008Est. completion: Dec 201325 patients
Phase 2Completed
NCT00695292Pfizersunitinib

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

Start: Jun 2008Est. completion: Sep 201237 patients
Phase 2Completed
NCT00668863Pfizersunitinib

Study Of Sunitinib With FOLFIRI In Colorectal Cancer

Start: May 2008Est. completion: Sep 201071 patients
Phase 2Completed
NCT00662025Pfizersunitinib

Study Of Sunitinib With Capecitabine In Breast Cancer

Start: Apr 2008Est. completion: May 201263 patients
Phase 2Completed
NCT00609622Pfizersunitinib

Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

Start: Apr 2008Est. completion: Jul 2011191 patients
Phase 2Terminated
NCT00556049Pfizersunitinib

Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Start: Dec 2007Est. completion: Dec 201472 patients
Phase 2Completed
NCT00535379Pfizersunitinib

SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme

Start: Oct 2007Est. completion: Jan 201170 patients
Phase 2Unknown
NCT00550810Pfizersunitinib

Sutent Maintenance After Response to Taxotere

Start: Oct 2007Est. completion: Nov 201230 patients
Phase 2Unknown
NCT00480935Pfizersunitinib

A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

Start: Oct 2007Est. completion: Oct 20113 patients
Phase 2Terminated
NCT00589784Pfizersunitinib

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Start: Oct 2007Est. completion: Oct 201450 patients
Phase 2Completed
NCT00631618Pfizersunitinib

Clinical Trial of Sutent to Treat Metastatic Melanoma

Start: Sep 2007Est. completion: Mar 201212 patients
Phase 2Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
5m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
5m ago

Office Administrator

SystImmune
5m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
16m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
19m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
19m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 6,866 patients
Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)